[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
5-May-2014

[ | E-mail ] Share Share

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
www.twitter.com/UH_Cougars

Possible treatment for kidney disease in lupus studied at UH

Biomedical engineer Chandra Mohan receives grant from Alliance for Lupus Research

IMAGE: University of Houston biomedical engineer Chandra Mohan and his team aim to understand to what extent a specific molecular pathway is activated in lupus and whether it can be therapeutically...

Click here for more information.

HOUSTON, May 5, 2014 In the U.S. alone, more than 1.5 million people have lupus, a chronic autoimmune disease in which the immune system turns against itself, attacking a person's healthy tissue, cells and organs. The symptoms can range from debilitating pain and fatigue to organ failure.

One of the most common organs to be attacked by lupus is the kidney, manifesting in lupus nephritis. An estimated 40 percent of lupus patients develop this condition, which causes inflammation of the kidneys, impairing their ability to get rid of waste products and other toxins from the body effectively. Lupus nephritis is the leading cause of lupus-related deaths and results in tens of thousands of hospitalizations per year.

Dr. Chandra Mohan, a biomedical engineer at the University of Houston (UH), has a theory about the development of lupus nephritis and, if he's right, there may already be a treatment. Mohan was recently awarded a $200,000 grant from the Alliance for Lupus Research (ALR), the world's largest funder of lupus research, to study whether the interaction of three specific molecules is the cause of lupus nephritis. Through this grant, Mohan aims to understand to what extent this molecular pathway is activated in lupus and whether it can be therapeutically targeted using specific drugs.

"Currently, management of lupus involves the use of nonspecific drugs, such as steroids, that suppress the immune system. Our lab, however, is trying to find out the exact molecular mechanisms that lead to lupus," Mohan said. "These mechanisms belong to two classes. On the one hand, you have molecules and pathways that activate the immune system to attack your own body cells. The second set of molecules focus on the kidneys once the immune system is activated by lupus. Our present research and grant focuses on this second molecular cascade, and we want to see whether we can target the kidneys to offer therapeutics that lessen the chance of a patient developing kidney disease once they've developed lupus."

IMAGE: Biomedical engineer Chandra Mohan and his colleague Yong Du received a $200,000 grant from the Alliance for Lupus Research to study whether the interaction of three specific molecules is the...

Click here for more information.

Specifically, Mohan is referring to a pathogenic cascade found in inflammatory kidney diseases, which includes three molecules kallikreins, bradykinin and one of two bradykinin receptors. High levels of these three specific molecules work together to cause the disease.

The kallikrein enzyme leads to the production of bradykinin, which is a peptide that helps regulate blood pressure and inflammation. The kidneys also have elevated levels of the two bradykinin receptors (B1 and B2), which are proteins that chemically bond with bradykinin to set certain biological processes in motion. While the B2 receptor plays a role in disease protection, the B1 receptor induces inflammation and fibrosis in the kidneys, eventually leading to kidney failure. In lupus patients, B1 is more prevalent. The goal of the ALR grant is to determine whether this pathway can be blocked, thus preventing the activation of certain receptors in the kidneys.

Mohan and his research team, including research assistant professor Yong Du, are working with a drug already in clinical trials for other kidney diseases. This drug acts as an inhibitor that attaches to B1 and physically blocks it from bonding with bradykinin. No bond means no kidney inflammation. Mohan's group will study how subjects with lupus nephritis respond to this inhibitor drug.

"We will compare the efficacy of this novel therapy with that of steroids, which is currently the most common standard of care, in suppressing lupus nephritis," Mohan said. "If these subjects show significant improvement, we will have established the link between lupus nephritis and the pathogenic cascade we are targeting, as well as show that the inhibitor is an excellent candidate for treating lupus nephritis."

IMAGE: Dr. Chandra Mohan is studying a pathogenic cascade found in inflammatory kidney diseases that includes three molecules -- kallikreins, bradykinin and one of two bradykinin receptors. High levels of these...

Click here for more information.

Mohan believes there is a high chance this will work, since the company that developed the drug has already gone through many libraries of molecules and selected this inhibitor, which seems to be working in clinical trails with other renal diseases. Additionally, the safety of the inhibitor has already been established, so if his team's experiments go well, he thinks the transition to clinical trials would come quickly.

"To put it in perspective, lupus affects so many pathways and cells. So, if we are successful, this would be one of many different ways of attacking such a complex disease," Mohan said. "We do believe this drug would be more efficacious than the currently available steroids, which essentially dampen the entire immune system."

Mohan, who is a Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering in the Cullen College of Engineering, focuses on the genetics of systemic lupus erythematosus (often simply called SLE or lupus). A major goal of his lab is trying to detect who would develop lupus or other chronic rheumatic autoimmune diseases, such as arthritis, and whether individuals will go on to develop kidney, lung, joint, skin or brain diseases, which are all common complications of SLE.

###

About the University of Houston

The University of Houston is a Carnegie-designated Tier One public research university recognized by The Princeton Review as one of the nation's best colleges for undergraduate education. UH serves the globally competitive Houston and Gulf Coast Region by providing world-class faculty, experiential learning and strategic industry partnerships. Located in the nation's fourth-largest city, UH serves more than 39,500 students in the most ethnically and culturally diverse region in the country. For more information about UH, visit the university's newsroom at http://www.uh.edu/news-events/.

About the Cullen College of Engineering

The UH Cullen College of Engineering, established in 1941, is accredited by the Engineering Accreditation Commission of ABET. More than 4,600 students are enrolled in engineering courses 3,536 undergraduates, as well as 817 master's and doctoral students in biomedical, chemical, civil, computer, electrical, environmental, geosensing systems, industrial, mechanical and petroleum engineering. The college also offers interdisciplinary graduate programs in subsea, aerospace, materials, and computer and systems engineering. Chemical and mechanical engineering have ranked among the top programs nationally.

For additional news alerts about UH, follow us on Facebook at http://www.facebook.com/UHNewsEvents and Twitter at http://twitter.com/UH_News.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.